Collection of Circulating Biomarkers in Pancreatic Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Obtaining blood for analysis of various circulating biomarkers.
- Who it may be relevant to
- Registry conditions: Pancreas Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer
Overview
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Interventions
- Other Obtaining blood for analysis of various circulating biomarkers
4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
Primary outcome measures
- To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use. [Time frame: Through study completion, an average of 1 year]
Secondary outcome measures (2)
- To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response. [Time frame: Through study completion, an average of 1 year]
- To integrate the data and specimens to permit the most informative clinical-biologic research platform. [Time frame: Through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
- The subject must be a patient of the University of Pennsylvania
- The subject must be able to provide informed consent
- The subject must be 18 years of age or older
Exclusion criteria
. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Abramson Cancer Center at University of Pennsylvania — Philadelphia
Identifiers
NCT: NCT05743049 · UPCC 20222 · 852628